Assessment of the number of PFN1+CD326+ CTCs may be the most valuable indicator for the risk of lymph node metastasis: AUC, 0.92 (95% CI, 0.80–1.00), sensitivity, 85%, and specificity, 96%. This evidence concerns the gene PFN1 and metastatic malignant neoplasm in the lymph nodes.